Table 3. . Sampling of current studies incorporating novel agents in Richter's syndrome specific cohorts.

Study agents	Phase	Study population	NCT#
Venetoclax + REPOCH	II	RS	NCT03054896
Ibrutinib + Obinutuzumab + CHOP	II	RS	NCT03145480
Obinutuzumab + HDMP + Lenalidomide	II	RS	NCT03113695
Blinatumumab	II	RS	NCT03121534
Selinexor + RICE	II	R/R BNHL, RS cohort	NCT02471911
Ublituximab + Umbralisib + Pembrolizumab	I/II	R/R CLL or RS	NCT02535286
Nivolumab and Ibrutinib	II	R/R CLL or RS	NCT02420912
Acalabrutinib and Vistursertib	II	R/R DLBCL or RS	NCT03205046

CHOP: Cyclophosphamide, doxorubicin, prednisone; CLL: Chronic lymphocytic leukemia; DLBCL: Diffuse large B-cell lymphoma; HDMP: High-dose methylprednisone; R/R: Relpased/refractory; REPOCH: Rituximab, etoposide phosphate, prednisone, vincristine sulphate, cyclophosphamide, doxorubicin hydrochloride; RICE: Rituximab, ifosfamide, carboplatin, etoposide; RS: Richter's syndrome.